Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Eli Lilly and Company (NYSE:LLY) is one of the best strong buy growth stocks to buy right now. Reuters reported on May 1 that Foundayo, which is Eli Lilly and Company’s (NYSE:LLY) newly launched oral weight-loss drug, hit 5,612 prescriptions in the United States in the third week following its launch, as per analysts citing […]
Eli Lilly and Company (NYSE:LLY) is one of the best strong buy stocks to invest in according to billionaires. Cantor Fitzgerald lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,230 from $1,205 on May 1, reaffirming an Overweight rating on the shares. The firm told investors in a research note that the […]
Mounjaro generated $8.66 billion in sales in the first quarter.
Find insight on Amazon Pharmacy, Sanofi, Sunway Health and more in the latest Market Talks covering the health care sector.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Eli Lilly and Company (NYSE:LLY) is one of the 10 Strong Buy S&P 500 Stocks to Invest In. On May 4, 2026, Wolfe Research said the FDA received a report on April 30 through its Adverse Event Reporting System involving a case of serious hepatic failure in a patient treated with Eli Lilly and Company […]
LONDON/COPENHAGEN, May 7 (Reuters) - Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pricing pressure. Denmark's Novo, which has struggled to keep pace with U.
When the campus is complete, it will produce several of Lilly’s APIs and genetic medicines to serve US patients.
Novo Nordisk (NYSE:NVO) raised its 2026 full year guidance after the launch of its oral Wegovy weight loss pill in the U.S. Prescriptions for the oral version have surpassed 2,000,000 since January, signaling strong demand for the new format. The update comes during a period of intense competition with Eli Lilly and ongoing pricing pressures in the weight loss drug market. Novo Nordisk, trading at $45.76, sits at the center of the current weight loss drug story, with oral Wegovy adding a...
Eli Lilly's new oral weight loss drug Foundayo is under scrutiny after an FDA-reported case of liver failure and other serious adverse events soon after approval. The product has seen rapid early uptake, raising questions about safety monitoring and long term risk management for NYSE:LLY. At the same time, Eli Lilly announced a record $4.5b U.S. manufacturing build out to support obesity and diabetes drugs and its first genetic medicines facility. Eli Lilly, trading at $987.05, sits at the...
Eli Lilly, Western Digital and Vertiv are drawing attention as AI demand, GLP-1 drugs and data center growth fuel momentum.
While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.
Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.
Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to invest in for the next 2 years. On April 30, Eli Lilly delivered a powerful performance for Q1 2026, with revenue surging 56% to $19.8 billion. This growth was fueled by a 65% increase in volume, led by the strong demand for […]
Eli Lilly and Co. shares are trading higher on Tuesday as the company is reporting new data on its treatment for ulcerative colitis (UC). Omvoh Shows Durable Disease Clearance Disease clearance was evaluated among patients who achieved clinical remission with Omvoh at one year in the LUCENT-2 maintenance study and continued treatment in LUCENT-3, an open-label extension study. Eli Lilly’s recent data from the LUCENT-3 clinical trial shows that over 63.5% of patients treated with Omvoh (mirikizum
(Bloomberg) -- Eli Lilly & Co. sold $9 billion of investment-grade bonds Wednesday — the company’s biggest-ever issuance — as it looks to finance an acquisition spree. Most Read from BloombergUS Has Opened a Passage Through Hormuz, Central Command SaysUS Says Offensive Phase of Iran War Over as Ship Hit in StraitAnthropic Unveils AI Agents to Field Financial Services TasksDOJ Plans Intervention in Trump Supreme Court Carroll AppealTrump Pauses Plan to Guide Ships While Seeking Iran DealThe drugm
Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report tied to the company’s new oral obesity drug Foundayo, but shares recovered as analysts argued the reaction may have been overdone. The episode shifted investor attention toward the ...
LLY has cleared a historically bullish trendline on the charts
Health care stocks were mixed Wednesday afternoon, with the NYSE Health Care Index increasing 0.1% a
Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.
(Updates with the company's response in the fourth paragraph.) Eli Lilly (LLY) is looking to rais
While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
The Danish drugmaker is riding a wave of peptide craziness as its weight loss tablet crushes its U.S. debut.
Investors are concerned about where the stock market is headed this year. The ongoing geopolitical tensions, inflation concerns, and economic uncertainties are weighing on the market. If you are worried about a market downturn in the near future, there are stocks that can continue to stand strong. The S&P 500 has gained 5% this year, ... If You Want to Beat the Market, Start With These 3 Stocks
The drugmaker's total Indiana capital commitments since 2020 now exceed $21 billion, with a new genetic medicine facility opening in Lebanon
The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of
In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
